Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915910 | 0.82 | GPR35 (0.46) | GPR35PTK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL401252 | 0.78 | HCAR2 (0.38) | GPR35PTK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3156800 | 0.78 | CYP1A2 (0.54) | GPR35PTK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL14011276 | 0.77 | NPSR1 (0.50) | ALDH1A1CYP1A2LMNAHPGDMEN1 | |
| SCHEMBL14011277 | 0.75 | CYP1A2 (0.34) | CYP1A2CYP3A4ATMHPGDCYP2C9 | |
| SCHEMBL31495905 | 0.75 | GPR35 (0.45) | GPR35PTK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5513393 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP3A4LMNAHPGD | |
| SCHEMBL399721 | 0.74 | HCAR2 (0.38) | GPR35ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13330260 | 0.74 | GPR35 (0.40) | GPR35ALDH1A1CYP1A2CYP3A4LMNA | |
| SCHEMBL399174 | 0.74 | ATM (0.49) | GPR35PTK2ALDH1A1ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465806-B2 | Pyrrole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-16 | — | — | US | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| CN-1926137-A | Pyrrole-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1725550-A2 | PYRROLE-DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085239-A2 | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-3966739-A | ADRENOLYTIC, HYPOTENSIVE, SEDATIVE, ANTISEROTONINIC | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | GPR35 88/4885PTK2 4001/4885ALDH1A1 2144/4885 |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | F12, F2, F5 | GPR35 4380/4885PTK2 1908/4885ALDH1A1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.